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The aim of this study was to identify deregulated transcription factors (TFs) in colorectal cancer (CRC) and to evaluate their relation
with the recurrence of stage II CRC and overall survival. Microarray-based transcript profiles of 20 normal mucosas and 424 CRC
samples were used to identify 51 TFs displaying differential transcript levels between normal mucosa and CRC. For a subset of these
we provide in vitro evidence that deregulation of the Wnt signalling pathway can lead to the alterations observed in tissues.
Furthermore, in two independent cohorts of microsatellite-stable stage II cancers we found that high SOX4 transcript levels
correlated with recurrence (HR 2.7; 95% CI, 1.2–6.0; P¼0.01). Analyses of B1000 stage I–III adenocarcinomas, by
immunohistochemistry, revealed that patients with tumours displaying high levels of CBFB and SMARCC1 proteins had a
significantly better overall survival rate (P¼0.0001 and P¼0.0275, respectively) than patients with low levels. Multivariate analyses
revealed that a high CBFB protein level was an independent predictor of survival. In conclusion, several of the identified TFs seem to
be involved in the progression of CRC.
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Colorectal cancer (CRC) accounts for about 13% of all cancers and
it is the second most common cause of cancer death in the western
world (Parkin, 2001). Patients presenting with stage II CRC
(no lymph node or distant metastases) have a 5-year survival of
75–80% when surgically treated. Surgical resection is highly
effective in localised disease, but a significant proportion of stage
II patients (20–25%) experiences recurrence and dies from the
disease. Currently, it is not possible to accurately differentiate
between groups of stage II patients with good and poor prognosis;
consequently, there is an acute need for biomarkers that can
distinguish between these two groups (Wang et al, 2004).
Molecularly, CRC can be divided into two major subgroups:
microsatellite-stable (MSS) and -unstable cancers (MSI). The two
subgroups have a different clinical disease course, but are
otherwise very similar. The mechanism responsible for MSI is
known to be a failure of the DNA mismatch repair system.
Recently, whole-genome transcriptional profiling studies have
shown that there are profound transcriptional differences between
MSS and MSI cancers (Giacomini et al, 2005; Kruhoffer et al,
2005). However, the causal mechanisms for these differences
remain unclear. The biological and clinical behaviour of CRC is
affected by multiple molecular pathways controlling cellular
processes like differentiation, migration, replication, DNA repair,
proliferation and apoptosis (Sancho et al, 2004); one particularly
well-studied pathway is the Wnt pathway (de Lau et al, 2007).
Ultimately, the transcriptional responses mediated by these
pathways are controlled and exercised by transcription factors
(TFs). In normal tissue, tight control of the levels of TFs is crucial
to maintain tissue homoeostasis and, hence, many TFs have been
found to be oncogenic when their expression is deregulated or
when their functionality is altered through fusion with other genes
(Look, 1997). An improved understanding of which TFs affect
cancer biology may lead to improved ability to predict clinical
outcome and discovery of novel therapeutic strategies.
In this study, we used microarray expression profiling to
identify 51 TFs significantly deregulated in CRC. The list included
not only several TFs known to be deregulated in CRC but also
many for which this information was novel. The expression of the
51 TFs was further investigated in relation to clinically important
CRC subgroups. These analyses showed that 12 TFs were
differentially expressed between the MSS and MSI tumour
subgroups, that a high transcript level of one TF (SOX4) was
significantly associated with poor outcome of stage II MSS cancer
and that high protein levels of CBFB and SMARCC1 were
correlated with increased overall survival of CRC. In relation to
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sthe mechanisms causing the TF deregulation, we provide evidence
that deregulation of the Wnt pathway influences the expression
level of B20% of the 51 TFs.
MATERIALS AND METHODS
Patients and samples
Colorectal samples from a total of 444 patients, comprising 20
adjacent normal mucosa and 424 primary colorectal carcinomas,
were used for array-based transcriptional profiling. The 20
adjacent normal mucosa samples were all collected from non-
cancer areas located orally for the tumour. None of the patients
had received preoperative chemo- and/or radiotherapy. The
samples were organised into two data sets. The first data set
termed ‘HG_U133A’ is a subset of a previously published set of
transcription profiles (Kruhoffer et al, 2005) and consisted of 10
adjacent normal mucosa and 80 colon cancer samples, comprising
53 stage II and 27 stage III cancers with a median age at diagnosis
of 68.5 years (range 36–87 years). The MSS/MSI status was known
for 76 of the 80 cancers (25 MSI and 51 MSS). The second data set
termed ‘HG_U133 plus 2.0’ consisted of 10 adjacent normal
mucosa and 344 cancer samples (288 located in the colon and 56 in
the rectum). The cancer samples comprised 23 stage I, 287 stage II,
22 stage III and 12 stage IV cancers with a median age at diagnosis
of 70 years (range 29–94 years). The MSS/MSI status was known
for 331 of the 344 cancers (73 MSI and 258 MSS).
For the ‘HG_U133 plus 2.0’ set, time to recurrence information
was available for 326 of the 332 stage I–III cancers. The median
duration of follow-up was 59.8 months (range 12.8–145.6 months)
for the 274 patients without recurrence as the first event and 18.7
months (range 1.2–78.7 months) for the 52 patients with distant
recurrence as the first event.
Detailed lists of the clinicopathological data available for the 444
samples can be found in Supplementary Tables 1 and 2. Informed
consent was obtained from all patients according to local ethical
regulations, and all studies were approved by local ethical
committees according to the Helsinki Declaration.
Three human colorectal carcinoma tissue microarrays (TMAs)
were used for immunohistochemistry (IHC) analysis. A commer-
cial TMA (catalogue no. COCA 912-5-OL; BioCat, Heidelberg,
Germany) for the evaluation of associations of the normal
adenoma-carcinoma sequence with 71 colorectal specimens (10
normal colon mucosa, 10 adenoma, 40 stage I–IV adenocarcino-
mas and 11 liver metastasis), a custom-made stage II TMA
containing 51 stage II adenocarcinomas and 50 normal mucosa
specimens, and a large custom-made TMA containing CRC
biopsies from 1461 patients (Went et al, 2006). The latter TMA
was used for survival analyses. Therefore, patients with missing
values for any of the following parameters gender, age at surgery,
tumour location, TNM stage and survival time were excluded.
Likewise, patients who died of surgical complications (dead within
30 days of surgery) were excluded, leaving 1283 out of 1461
patients for survival analysis. Their median age at diagnosis was 71
years (range 30–96 years). The 1283 cancers comprised 177 stage I,
492 stage II and 614 stage III cancers. The median duration of
follow-up was 52.4 months (range 1–152 months). Data on post-
surgery radio- or chemotherapy were not available. Detailed
clinicopathological data of the TMA specimens are given in
Supplementary Tables 3A, 4 and 5. The WHO/UICC-TNM staging
system was used for staging of the adenocarcinomas.
Labelling, hybridisation, normalisation and statistical
analysis of microarrays
Labelling of RNA, hybridisation and scanning of HG_U133 plus 2.0
and Human Exon 1.0 ST arrays (Affymetrix, Santa Clara, CA, USA)
were performed as described earlier (Dyrskjot, 2003; Thorsen et al,
2008). The Human Genome U133A GeneChip array-based
transcription profiles used in this study is a subset of a previously
published set of transcription profiles (Kruhoffer et al, 2005).
GC-content corrected robust multiarray analysis (GC-RMA)
normalisation of the U133 plus 2.0 arrays and iterPLIER normal-
isation of the Exon 1.0 ST arrays were performed using the
software packages ArrayAssist (Stratagene, La Jolla, CA, USA) and
Expression Console v1.1 (Affymetrix), respectively. Differentially
expressed genes were identified using a Benjamini and Hockberg-
corrected ‘Two class unpaired’ statistical tests.
Approach for the identification of transcriptionally
deregulated TFs
A list of candidate TFs was generated by querying the Gene
Ontology (GO) database for genes linked to the GO term
‘transcription’. In this way, the Affymetrix HG_U133A array was
found to contain probe sets for 1026 potential TFs (1026 unique
Entrez Gene IDs). To identify if any of these candidate TFs were
deregulated in CRC compared with normal mucosa, we used the
two independent sets of array-based transcriptional profiles
described in the ‘Patients and samples’ section. The candidate
TFs with an average numerical log2 fold change of at least 1
(1 on log2 scale, corresponds to a fold change of 2 on a linear
scale) that were significantly deregulated (Po10
 4 after Benjamini
and Hochberg correction) in the ‘HG_U133A’ set (80 cancers/10
normals) were taken further for validation in the second larger and
independent set ‘HG_U133 plus 2.0’ (344 cancers/10 normals).
Transcription factor deregulation was considered significant if a
fold change of at least 1 (in the same direction as in the
‘HG_U133A’ set) with a P-value lower than 10
 4 was obtained in
the validation set.
Real-time RT–PCR
Quantitative real-time RT–PCR (qRT–PCR) was performed on a
7900HT Real-Time PCR System (Applied Biosystems, Foster City,
CA, USA) using the relevant (TaqMan or SYBR Green) Master Mix
(Applied Biosystems). Predesigned TaqMan assays were used to
measure RB1 (Hs01078066_m1) and E2F3 (Hs00605457_m1)
(Applied Biosystems). For normalisation, the gene Ubiquitin C
(UBC) was employed. We have demonstrated earlier the suitability
of UBC as a normalisation gene for analysis of normal mucosa and
CRC specimen sample sets (Andersen et al, 2004). The UBC primer
sequences have been published earlier (Andersen et al, 2004).
cDNA was generated using the Superscriptt cDNA synthesis kit
(Invitrogen, Carlsbad, CA, USA) with random nonamer primers
and RNAse inhibitor (Ambion, Austin, TX, USA). Each measure-
ment was performed in triplicate, and no-template controls were
included for each assay. Relative expression values were obtained
using a four-point 10-fold dilution curve. The dilution curve was
created using a cDNA pool of each of the test cDNAs.
Cell culturing
Dominant-negative TCF1 (dnTCF1)-inducible LS174T-derived cell
lines have earlier been described (van de Wetering et al, 2002) and
were a kind gift from Dr Hans Clevers (The Hubrecht Laboratory,
Utrecht, The Netherlands). The cell lines were cultured and
dnTCF1 induced by doxycycline as described earlier (Schepeler
et al, 2007). The cell lines were free from mycoplasm contamina-
tion as verified by the MycoSensort PCR assay kit (Stratagene)
according to the manufacturer’s instructions. Cells were harvested
at 0 and 12h after doxycycline induction. mRNA for array-based
transcript profiling was extracted using the GenElutet Mammalian
total RNA miniprep kit (Sigma-Aldrich, Brandlay, Denmark).
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Mouse monoclonal antibodies usable for IHC and immunoblotting
were available for the TFs CBFB (catalogue no. ab11921 (clone
141,4,1); Abcam, Cambridge, UK), E2F3 (catalogue no. 05-551;
Upstate, Charlottesville, VA, USA) and SMARCC1 (catalogue no.
sc-32763 (DXD7); Santa Cruz Biotechnology, Santa Cruz, CA,
USA). A rabbit polyclonal anti-Sox4 antibody (catalogue no.
AB5803; Chemicon International Inc., Temecula, CA, USA) usable
for IHC was also available.
The specificity of the E2F3 and SMARCC1 antibodies was
validated by immunoblot analysis of COS7 cells transiently
transfected with expression plasmids containing full-length cDNAs
(Supplementary Figures 1A and B). The specificity of the CBFB
antibody was validated by immunoblot analysis of normal mucosa
and colon cancer, which yielded bands corresponding to the
known CBFB isoforms (Supplementary Figure 1C). The SOX4
antibody did not work in western blot analysis. However, we have
earlier used IHC to investigate SOX4 protein expression in bladder
cancer (Aaboe et al, 2006). Hence, bladder cancer specimens were
used as positive controls for the SOX4 antibody. A pan-leukocyte
marker, CD45, in the form of the mouse monoclonal anti-CD45
antibody (catalogue no. MS-240-P1; Neomarkers/Lab Visions
corp., Fremont, CA, USA) was used to identify infiltrating
lymphocytes (Woodford-Thomas and Thomas, 1993).
Immunohistochemistry
Standard indirect staining procedures were used for IHC (Went
et al, 2006). In brief, paraffin was removed followed by blocking of
endogenous peroxidase activity, heat-induced epitope demasking
and blocking to prevent unspecific binding. Then primary
antibodies were applied; the following antibodies were used,
anti-CBFB (1:1800), anti-SMARCC1 (1:150), anti-E2F3 (1:200),
anti-SOX4 (1:800) and anti-CD45 (1:600). Detection was per-
formed using the Envision system (DakoCytomation, Glostrup,
Denmark). Finally, the sections were counterstained with haema-
toxylin.
Semiquantitative scoring of intensity (negative, 0; weak, 1;and
strong, 2) and fraction of positive cancer cells (negative, 0; less
than half, 1; and more than half, 2) was undertaken independently
by two investigators. Nuclear and cytoplasmic staining was scored
separately. Tissue microarray cores that were missing or contained
fewer than 10 cancer cells or demonstrated significant artefacts
were not scored. Kappa statistics was used to evaluate the
agreement between the observers. In all scoring categories
(intensity, fraction, nuclear and cytoplasmic) a good-to-very good
inter-observer agreement was obtained for all investigated TFs
(Kappa statistic values ranging from 0.73 to 1.00, median 0.90).
The scores were converted into simple categories of negative, weak
and strong staining using the following formula: negative: intensity
0 and fraction of positive cells 0; weak: intensity 1 and fractions 1
and 2, and intensity 2 and fraction 1; strong: intensity 2 and
fraction 2.
Statistical analysis
The software used for statistical analysis was STATA 9.2
(StataCorp, College Station, TX, USA). Fisher’s exact and w
2 tests
were used to compare TF expression and clinical and morpholo-
gical tumour characteristics.
For each individual IHC score (nuclear and cytoplasmic),
survival analysis was performed. For simplicity, the nuclear and
cytoplasmic scores were combined when they showed the same
statistical trend. The scores were combined using the following
formula: negative: both scores were negative; weak: if neither score
was strong and one or both were weak; and strong: one or both
scores were strong. Survival curves were plotted according to
Kaplan–Meier. Univariate analysis was performed using the log-
rank test or the Cox proportional hazards model. Multivariate
analysis was performed using the Cox proportional hazards
regression model. P-values less than 0.05 were considered
significant.
RESULTS
Identification of deregulated TF transcripts in colorectal
cancer
By comparing transcript profiles of normal mucosa and CRC
samples in two independent sample sets, covering a total of 20
normal mucosa and 424 adenocarcinoma samples, we identified 51
TFs that showed a significant (Po10
 4, Benjamini and Hochberg
corrected) fold change (of at least 2) from normal to cancer in both
data sets. Fourteen of these TFs were downregulated and 37
upregulated (Table 1). The list included not only several TFs
known to be deregulated in CRC, for example c-MYC (He et al,
1998) and SOX9 (Blache et al, 2004), but also many for which this
information was novel for example, CBFB and SMARCC1. Below
we have validated four of the latter TFs, the others will have to be
validated in future studies.
Transcriptional analysis of E2F3 and RB1
One of the 51 deregulated TFs was E2F3, which belongs to the
family of E2F TFs. The E2F factors and the tumour suppressor RB1
constitute the key players in the RB/E2F pathway, a critical
regulator of G1/S cell cycle transition and hence proliferation.
Mutational inactivation of this checkpoint has been associated
with many cancers, but not CRC (Nevins, 2001). Our transcript
profiling data from the ‘HG_U133 plus 2.0’ data set (10 normal
mucosa samples and 344 cancers) showed that the average E2F3
transcript level was 1.67-fold (log2 scale) higher in cancer than in
normal mucosa (Table 1), whereas RB1 remained unchanged
(P¼0.26, two class unpaired test Benjamini and Hockberg
corrected). A comparison of the RB1/E2F3 transcript ratios
revealed a significant reduction of  1.97 fold (log2 scale) from
normal mucosa to cancer (P¼8.96 10
 8, Student’s t-test).
A similar reduction was found in the ‘HG_U133A’ data set
(10 normal mucosa samples and 80 cancers) with the average
RB1/E2F3 ratio dropping  0.63-fold (log2 scale) from normal
mucosa to cancer (P¼0.019, Student’s t-test). To validate that the
reduction was not an artefact of measuring the transcript levels
using array technology, we selected 60 samples (10 normals and 50
randomly selected cancers) from the HG_U133 plus data set for
qRT–PCR analysis. Quantitative RT–PCR confirmed that the E2F3
transcript level was increased in cancer (2.22-fold, log2 scale;
P¼1.26 10
 7, Student’s t-test) and that the average RB1/E2F3
ratio was reduced by  0.87-fold (log2 scale) from normal mucosa
to cancer (P¼3.52 10
 6, Student’s t-test).
E2F3 IHC analysis of a commercial TMA containing normal
mucosa as well as benign and malignant colorectal specimens
revealed that E2F3 was significantly higher expressed also at the
protein level in the majority of cancers compared with normal
mucosa (Figure 1A–F). The data also indicated that the E2F3
protein level might be associated with tumour progression as a
significant difference was observed between adenocarcinomas and
metastases (Figure 1F). To investigate if the E2F3 protein level was
associated with TNM stage and overall survival, IHC was applied to
a large custom-made TMA with stage I–III adenocarcinomas, for
which follow-up information was available. A borderline-signifi-
cant association was found for TNM stage (P¼0.066, Fisher’s
exact test; Supplementary Table 3B). This resulted from a minor
but significant shift from strong to weak E2F3 staining from stage I
to II (P¼0.011, Fisher’s exact test), which was not repeated from
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expression level followed a stage-specific trend, we applied a non-
parametric test for trend (an extension of the Wilcoxon rank-sum
test (Cuzick, 1985)) that did not reach significance (P¼0.183).
Taken together the data indicate that there is no tight association
between the E2F3 protein level and TNM stage. Likewise, our
survival analysis did not identify any relationship between the
E2F3 protein level and overall survival (data not shown).
In Supplementary Table 3B, correlations of E2F3 with other
histopathological parameters are shown.
TF expression in microsatellite stable and unstable colon
cancers
Two major molecular subgroups of CRC have been discerned –
MSS and MSI cancers. As the cellular processes responsible for
Table 1 Fifty-one transcription factors deregulated in colorectal cancer
‘HG_U133A’ data set
a ‘HG_U133 plus 2.0’ data set
b
Gene
symbol
Entrez
gene ID
Probe
set ID
c
Transfac
ID
d
Transcription
actor class
d P-value
e Fold change
f P-value
e Fold change
f
HAND1 9421 220138_at T04373 Basic helix–loop–helix 1.76E 05  1.31 1.13E 09  1.19
HIS1 10614 202815_s_at 9.84E 08  1.15 4.22E 13  1.67
KLF4 9314 220266_s_at C2H2 zinc finger
g 4.74E 05  2.18 1.48E 09  3.53
MAF 4094 206363_at bZIP
g 9.84E 08  1.40 4.74E 22  3.02
MEF2C 4208 209200_at T01767 MADS box 1.17E 07  1.96 1.36E 10  2.86
NR1H4 9971 206340_at T04498 Cys4 zinc finger of nuclear receptor type 2.40E 08  2.70 4.17E 07  1.92
NR3C2 4306 205259_at T00513 Cys4 zinc finger of nuclear receptor type 3.52E 05  2.20 7.39E 14  4.02
NR5A2 2494 210174_at T02771 Cys4 zinc finger of nuclear receptor type 1.37E 05  1.66 4.39E 14  3.56
PPARGC1A 10891 219195_at 5.49E 05  1.14 2.15E 11  2.66
SLC26A3 1811 215657_at 6.99E 08  2.66 6.17E 14  4.93
SPIB 6689 205861_at T01401 Ets 1.92E 11  2.71 4.08E 13  2.03
SSBP2 23635 203787_at 1.93E 07  1.23 1.29E 12  2.47
VDR 7421 204254_s_at T00885 Cys4 zinc finger of nuclear receptor type 2.43E 06  1.20 4.03E 08  1.36
ZBTB16 7704 205883_at C2H2 zinc finger
g 6.86E 08  1.32 6.74E 13  1.36
ARNTL2 56938 220658_s_at Basic helix–loop–helix
g 1.74E 05 1.58 2.28E 06 1.93
BHLHB2 8553 201170_s_at Basic helix–loop–helix
g 5.07E 08 1.96 1.29E 11 2.01
CBFB 865 202370_s_at T02259 CBF_beta 2.12E 06 1.32 1.49E 13 1.49
CBX4 8535 206724_at 8.15E 05 1.11 9.62E 10 1.71
CEBPB 1051 212501_at bZIP
g 1.83E 05 1.00 6.84E 13 1.59
DNMT1 1786 201697_s_at Zinc finger
g 2.80E 05 1.18 7.61E 11 1.44
E2F3 1871 203693_s_at T01545 Fork head/winged helix 2.46E 09 1.59 6.60E 14 1.69
FOXA2 3170 210103_s_at T02413 Fork head 3.12E 07 2.06 2.75E 05 1.80
FOXM1 2305 202580_x_at T02516 Fork head 1.17E 07 2.29 5.87E 15 3.10
GTF2IRD1 9569 218412_s_at TFII-I
g 3.18E 12 2.79 3.00E 22 2.77
GTF3A 2971 215091_s_at C2H2 zinc finger
g 3.54E 06 1.61 7.57E 13 2.00
HIRA 7290 217427_s_at 6.99E 08 1.43 2.61E 06 1.13
HMGA1 3159 206074_s_at HMG
g 1.91E 08 1.57 1.02E 19 2.50
HMGB1 3146 200679_x_at HMG
g 1.08E 05 1.26 5.54E 09 1.32
MTA1 9112 211783_s_at Zinc finger
g 6.96E 06 1.35 2.12E 11 1.57
MYC 4609 202431_s_at T00140 bHLH-ZIP 4.10E 06 1.99 6.10E 14 2.66
NFE2L3 9603 204702_s_at bZIP
g 5.02E 07 1.80 5.15E 24 3.06
NME2 4831 201268_at T00706 5.95E 09 1.08 2.39E 19 1.26
NPM1 4869 221923_s_at 5.22E 08 1.76 1.16E 12 1.59
PHB 5245 200658_s_at 5.01E 07 1.17 7.57E 10 1.25
POLR3K 51728 218866_s_at Zinc finger
g 8.15E 05 1.00 3.67E 06 1.12
RUNX1 861 209360_s_at T01067 Runt 1.86E 05 1.30 3.34E 07 1.35
SCML1 6322 218793_s_at 1.32E 05 1.74 3.67E 07 1.68
SMARCA4 6597 213720_s_at Bromo domain
g 7.53E 07 1.11 2.42E 12 1.15
SMARCC1 6599 201074_at Myb-like DNA-binding region
g 8.84E 07 1.28 3.98E 11 1.15
SOX4 6659 213668_s_at T01277 HMG 2.15E 07 2.84 1.06E 27 4.42
SOX9 6662 202935_s_at T01853 HMG 1.38E 09 3.07 6.29E 27 3.91
TEAD4 7004 41037_at TEA DNA-binding domain
g 7.81E 10 2.24 2.99E 27 3.58
TFDP1 7027 212330_at T01548 Fork head 7.04E 05 1.12 5.24E 07 1.21
TGIF 7050 203313_s_at T04076 Homeo 1.17E 07 1.61 3.83E 20 2.44
THRAP4 9862 213043_s_at 2.51E 06 1.14 4.09E 15 1.59
TRIB3 57761 218145_at 1.66E 06 2.17 9.39E 20 3.73
TRIM29 23650 202504_at Zinc finger
g 6.99E 08 3.84 3.50E 11 4.39
TRIP13 9319 204033_at 2.40E 08 2.37 4.76E 23 3.32
ZNF238 10472 212774_at T05040 C2H2-type zinc finger
g 8.98E 07 1.38 6.55E 09 1.24
ZNF263 10127 203707_at C2H2-type zinc finger
g 3.97E 06 1.05 1.58E 16 1.46
ZNF593 51042 204175_at C2H2-type zinc finger
g 6.99E 08 1.45 3.32E 24 2.51
aThe ‘HG_U133A’ data set consists of 10 normal mucosa and 80 colon cancer samples.
bThe ‘HG_U133 plus 2.0’ data set consists of 10 normal mucosa and 344 colorectal
cancer samples.
cAffymetrix GeneChip ‘HG_U133A’ and ‘HG_U133 plus 2.0’ probeset identifiers.
dAccording to TRANSFAC
s 7.0 – Public (http://www.gene-regulation.com/
pub/databases.html).
eBenjamini and Hockberg-corrected ‘Two Class Unpaired’ test for difference in expression level between normal mucosa and cancer samples.
fFold change
(on log2 scale)¼the average log value of the cancer samples subtracted the average log value of the normal mucosa samples.
gCharacteristic transcription factor domains
according to the Uniprot database (http://www.uniprot.org).
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subgroups are likely to be regulated by TFs, we wanted to
investigate the expression patterns of the deregulated TFs in MSS
and MSI cancers. To avoid tumour site from becoming a
confounding factor, the analysis was restricted to colon cancers.
This was motivated by the observation that MSI occurred more
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Figure 1 E2F3 expression detected by immunohistochemistry. E2F3 IHC analysis of the commercial TMA, COCA 912-5-OL, containing normal mucosa
as well as benign and malignant colorectal specimens demonstrated that although E2F3 was not expressed by normal epithelial cells (A) E2F3 was found
de novo synthesised by the majority of the investigated neoplastic tissues (B and C). The subcellular localisation of the de novo synthesised E2F3 protein was
in some tumours found to be primarily nuclear (B) and cytoplasmic in others (C). Adenocarcinomas with no E2F3 staining (negative) were also observed,
though only rarely (D). These were very similar to the ‘no primary’ antibody negative control (E). The frequency and intensity of E2F3 protein expression
(combining nuclear and cytoplasmic staining) in adenoma, adenocarcinoma and metastasis samples were significantly higher than in normal mucosa (F). The
same was the case when nuclear and cytoplasmic staining was evaluated individually (data not shown). The E2F3 IHC staining was evaluable and scored in 70
of the 71 tissue cores in the commercial TMA. P-values correspond to Fisher’s exact tests. ADC¼adenocarcinoma. All images are  20. Staining: brown,
E2F3; blue, haematoxylin counterstain.
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sfrequently in colon (24%) than rectal cancer (12.5%) in our
‘HG_U133 plus 2.0’ sample set. Similar observations have been
reported earlier (Ikeda et al, 2001). Naturally, only colon cancers
for which the MSS/MSI status was known were included. Hence,
from the ‘HG_U133A’ sample set, 76 of 80 colon cancers (51 MSS
and 25 MSI) were included and from the ‘HG_U133 plus 2.0’ data
set, 275 of 288 colon cancers (209 MSS and 66 MSI). To exclude
that TNM stage distribution was a confounding factor, we used
Fisher’s exact tests to compare the distribution of TNM stages in
the MSS and MSI subgroups. No significant differences were
observed (P40.05).
Comparison of the MSS and MSI subgroups revealed that 12 of
the 51 TFs were differentially expressed (Po0.05, Benjamini and
Hockberg-corrected ‘Two class unpaired’ test) in both data sets
(Table 2 and Supplementary Table 6). Ten TFs showed lower, and
two higher, expression in MSI relative to MSS cancer. A
comparison of the expression levels of the 12 TFs in normal
mucosa and MSS and MSI cancers revealed that FOXA2 was
significantly (Po0.01) deregulated in MSS but not MSI cancers
explaining why it was found to be differentially expressed between
MSS and MSI. The remaining 11 TFs were all deregulated (normal to
cancer) in both cancer subgroups (in the same direction), but the
degree of deregulation differed explaining why they were found to
be differentially expressed between MSS and MSI (data not shown).
TF expression in relation to recurrence of stage II CRC
Deregulation of TFs may lead to the development of cancer and
progression of disease (Look, 1997; Nesbit et al, 1999). Along these
lines we speculated if the transcriptional level of any of the
identified TFs (Table 1) might be involved in determining the
metastatic capacity of primary tumours. To test this hypothesis, we
investigated transcriptional profiles of two series of stage II CRCs
(an MSS and an MSI series), which were selected from our set of
287 stage II ‘HG_U133 plus 2.0’ transcription profiles. Twenty-
seven cases were excluded based on the following criteria: missing
MSS/MSI status (n¼11), missing follow-up (n¼6), follow-up
o40 months (n¼1) or distant recurrence to sites other than liver
or lungs (n¼9). The remaining 260 cases were divided into two
series based on their MSS/MSI status. None of the included cases
had received adjuvant therapy. The stage II MSS series consisted of
173 non-recurrent cases with a median duration of follow-up of
59.8 months (range 43.3–145.6 months) and 22 recurrent cases,
that is histologically verified liver and/or lung metastases, with a
median duration of follow-up of 16.7 months (range 4.9–78.7
months). Similarly, the MSI series consisted of 56 non-recurrent
cases with a median duration of follow-up of 59.8 months
(range 51.1–109.2 months) and nine recurrent cases with a
median duration of follow-up of 30.0 months (range 1.2–65.9
months). Unpaired t-tests indicated that three of the 51 TFs were
significantly associated (Po0.05) with recurrence of stage II MSS
cancer and 13 with recurrence of MSI stage II cancer (Table 2 and
Supplementary Table 7). From a recent report we extracted
Affymetrix HG_U133A transcriptional profiles of 25 non-recur-
rence and 25 recurrence (liver metastases) stage II MSS colon
cancers (Barrier et al, 2006). By analysing this independent data set
one of the three significant TFs (SOX4) from our MSS series was
validated (P¼0.0039, unpaired t-test). The other two TFs did not
reach significance. To our knowledge, no publicly available data
set of stage II MSI CRCs with follow-up information exists. Hence,
we have not been able to validate the 13 candidate markers of
recurrence of stage II MSI cancer.
Next we investigated the association between the SOX4
transcript level and recurrence-free survival. To enable survival
analysis, the SOX4 expression data were dichotomised with the
highest tertile classified as high and the lower two tertiles classified
as low. This cutoff was set based on associations within the MSS
stage II CRC cohort of this study before analysing the validation
cohort from Barrier et al (2006). As expected, the patients having
an SOX4 expression level in the highest tertile experienced a
significantly higher incidence of recurrence (P¼0.005, w
2 test) and
a shorter recurrence-free survival (Figure 2A, log-rank test
P¼0.0083 and univariate cox regression analysis P¼0.01; hazard
ratio 2.0; 95% CI, 1.18–3.51). Notably, this association was only
observed in our MSS series (Table 2), consistent with SOX4 being
differentially expressed between MSS and MSI tumours (Table 2).
In the validation data set from Barrier et al (2006), SOX4
expression in the upper tertile was also associated with a
significantly higher incidence (P¼0.005, Fisher’s exact test) of
recurrence and a shorter recurrence-free survival (log-rank test
P¼0.0092 and univariate cox regression analysis P¼0.01; hazard
ratio 2.7; 95% CI, 1.2–6.0). Recurrence-free survival as a function
of SOX4 expression is plotted in Figure 2B. Subsequently, we
wanted to investigate if the SOX4 transcripts observed in cancer
were also translated into protein. To address this question we
returned to our comparisons of normal mucosa and adenocarci-
nomas, which demonstrated increased transcript levels in the
adenocarcinomas (Table 1). We then performed a similar analysis
at the protein level by applying SOX4 IHC to a custom-made stage
II TMA. The IHC staining was evaluable in 37 normal mucosa and
49 adenocarcinoma tissue cores (all from patients independent
from the cohort investigated by transcriptional profiling). In
agreement with the transcript analysis, IHC revealed that both the
frequency and the expression level of SOX4 protein were generally
increased in adenocarcinomas, Po0.001 Fisher’s exact test (Figure
2C–H). Furthermore, the IHC analysis demonstrated that the
SOX4 protein found in the tumours was primarily of cancer cell
origin (Figure 2D and E). We did not have recurrence nor survival
information for the patients in the stage II TMA. Consequently, we
could not evaluate if the SOX4 protein level could also predict
recurrence of stage II CRC. Nor could we analyse if it was
associated with survival. However, this would be interesting to
investigate in a future study.
CBFB and SMARCC1 protein expression and association
with overall survival
Of the TFs not reported earlier to be associated with CRC, we
selected CBFB and SMARCC1 for IHC analysis based on the
availability of antibodies for which the specificity could be
validated in western blot analyses. To investigate CBFB and
SMARCC1 protein expression in normal and neoplastic tissues,
IHC was applied to a commercial TMA (COCA 912-5-OL)
containing tissue biopsies covering normal mucosa, adenoma,
Table 2 Transcription factors associated with MSI status, recurrence of
stage II CRC and Wnt signalling
TF transcript level in Up Down
MSI relative to MSS ARNTL2, HIS1 CBFB, FOXA2, GTF2IRD1,
GTF3A, HMGB1, RUNX1,
SMARCC1, SOX4, SOX9,
ZNF238
Recurrent relative to
non-recurrent stage II
MSS cancers
SOX4, TRIM29 KLF4
Recurrent relative to
non-recurrent stage II
MSI cancers
MAF, KLF4, ZBTB16 FOXM1, GTF3A, HIS1,
NPM1, PHB, POLR3K,
SMARCA4, TRIB3, TRIP13,
VDR
Cells with inactive Wnt
signalling relative to cells
with active Wnt signalling
BHLHB2, HIS1,
SSBP2, TRIM29
ARNTL2, MYC, SMARCA4,
SOX4, SOX9, TEAD4, TGIF
CRC¼colorectal cancer; MSS¼microsatellite stabile; MSI¼microsatellite instabile.
For detailed information on the sample sets investigated, the sizes of the fold changes
observed and the statistical tests applied see Supplementary Tables 6–8.
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sadenocarcinoma and liver metastases. No CBFB protein expression
was observed in normal epithelia (Figure 3A). SMARCC1 was
found to be weakly expressed in the basal half of the normal
colonic crypts (Figure 4A). CBFB was observed both in the nucleus
and in the cytoplasm of the neoplastic cells, whereas SMARCC1
was observed only in the nucleus in both normal and neoplastic
cells (Figure 3B and C and 4B, respectively). A comparison of IHC
staining for CBFB and CD45 (a pan-leukocyte marker) indicated
that CBFB was also expressed by a subset of stromal cells, in
particular lymphocytes, including lymphocytes infiltrating both
normal epithelia and cancer (Figure 3E). We then compared the
staining frequencies observed in normal mucosa, adenoma,
adenocarcinoma and liver metastasis. For simplicity, the nuclear
and cytoplasmic CBFB IHC scores were combined to a single CBFB
(the present study)
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Figure 2 Analysis of SOX4 transcript and protein expression levels. Shown are censored Kaplan–Meier curves for recurrence-free survival of MSS stage II
CRC according to the transcriptional expression level of SOX4 as measured by microarray expression profiling in this study (A) and the study by Barrier et al
(2006) (B). The P-values correspond to the log-rank test. To investigate whether the SOX4 protein expression level changed from normal mucosa to
adenocarcinoma, IHC was applied to a custom-made stage II TMA. The TMA tissue cores were not scored if they were missing, or contained fewer than 10
cancer cells, or demonstrated significant tissue or IHC staining artefacts. Hence, only 49 of the 51 adenocarcinoma and 37 of the 49 normal mucosa coresi n
the TMA were scored. In the majority of the normal mucosa samples, SOX4 was either not (C) or only weakly expressed. By contrast, a strong SOX4
staining was observed in more than 40% of the stage II adenocarcinomas. Often, the SOX4 protein was localised both in the cytoplasm and in the nucleus of
the cancer cells. In some adenocarcinomas, the SOX4 staining was strongest in the nucleus (D), whereas in others, the cytoplasm and the nucleus were
stained equally strong (E). Adenocarcinomas with no SOX4 staining (negative) were also observed, though only rarely (F). These were highly similar to the
‘no primary’ antibody negative control (G). The distribution of SOX4 IHC scores (combined nuclear and cytoplasmic staining) showed that both the
frequency and the intensity of SOX4 staining were increased in the adenocarcinomas compared with those in the normal mucosas (H). The same was the
case when the nuclear and cytoplasmic IHC scores were analysed individually (data not shown). The P-values were calculated using the w
2 test. All IHC
images are  20. Staining: brown, SOX4; blue, haematoxylin counterstain.
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sscore in these analyses. The frequency and intensity of CBFB
expression increased significantly (P¼0.01, Fisher’s exact test)
from normal mucosa to adenoma and again from adenoma to
adenocarcinoma (Po0.001, Fisher’s exact test). By contrast, the
staining frequency in liver metastases was significantly lower than
that in adenocarcinomas (Po0.001, Fisher’s exact test) (Figure 3F).
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Figure 3 CBFB protein expression and the relation to survival. The CBFB protein expression was investigated by IHC in normal mucosa, adenoma,
adenocarcinoma and metastases using the commercial TMA COCA 912-5-OL. Tissue microarray tissue cores were not scored if they were missing, or
contained fewer than 10 cancer cells, or demonstrated significant tissue or staining artefacts. Hence, of the 71 tissue cores in the commercial TMA, 68 were
scored for CBFB expression. The IHC analysis showed that whereas CBFB was not expressed by normal epithelial cells (A) CBFB was found de novo
synthesised by the majority of the investigated neoplastic tissues (B and C). The subcellular localisation of the de novo synthesised CBFB protein was in some
tumours found to be primarily nuclear (B) and cytoplasmic in others (C). Adenocarcinomas with no CBFB staining (negative) were also observed (D). Often
small intensely staining cells were seen in the stroma and infiltrating both the normal epithelia (A) and the cancer cells (C). Comparison of sections cut from
the same biopsies and stained with CBFB and CD45 (a pan-leukocyte marker) indicated that the small cells with intense CBFB staining represent infiltrating
leukocytes (E). The distribution of the CBFB IHC scores in normal mucosa, adenoma, adenocarcinoma and metastases illustrates that CBFB is de novo
synthesised in neoplastic tissue and that the frequency and intensity of the staining (combined cytoplasmic and nuclear staining) increases from adenoma to
adenocarcinoma, and then drops back down again in metastases (F). Similar results were reached when the cytoplasmic and nuclear staining were analysed
individually (data not shown). P-values correspond to Fisher’s exact tests. To investigate if the CBFB protein level was correlated with overall survival, IHC
was applied to a large custom-made TMA containing adenocarcinoma tissue cores from 1283 patients with available follow-up information. The CBFB IHC
staining was evaluable in 1009 of these patients. Shown in (G) are censored Kaplan–Meier curves as a function of the CBFB IHC scores (nuclear and
cytoplasmic scores combined). The individual survival curves for patients with negative and weak IHC scores were very similar, and they were therefore
treated as one group. Similar results were reached when the cytoplasmic and nuclear staining were analysed individually (data not shown). The P-value
corresponds to the log-rank test comparing the survival curves. See Supplementary Table 3A for a summary of the clinical characteristics and follow-up
information available for the 1009 patients. See Supplementary Table 3C for the distribution of the 1009 IHC scores and their correlations with the available
clinicopathological parameters. Arrow heads: infiltrating lymphocytes. Arrows: lymphoid nodules. All images are  20. Staining: brown, CBFB or CD45 as
indicated; blue, haematoxylin counterstain.
Figure 4 SMARCC1 protein expression and the relation to survival. The SMARCC1 protein expression was investigated by IHC in normal mucosa,
adenoma, adenocarcinoma and metastases using the commercial TMA COCA 912-5-OL. Tissue microarray tissue cores were not scored if they were
missing, or contained fewer than 10 cancer cells or demonstrated significant tissue or staining artefacts. Hence, of the 71 tissue cores in the commercial TMA,
68 were scored for SMARCC1 expression. The IHC analysis showed that in normal colon mucosa, SMARCC1 was weakly expressed in the lower third of
the crypts of (A). The inset in (A) represents an IHC analysis of the same specimen but without the counterstain, making the SMARCC1 staining at the
bottom of the crypts stand out more clearly. In contrast to the normal mucosa, the SMARCC1 staining seen in the neoplastic tissues was often more intense
and uniformly distributed (B). Neoplastic tissues with no SMARCC1 staining (negative) were also observed (C). The subcellular localisation of the
SMARCC1 protein was in both the normal epithelial cells and in the neoplastic cells restricted to the nucleus (A and B). As SMARCC1 was already
expressed by the normal mucosa, comparisons of the SMARCC1 IHC scores in normal mucosa, adenocarcinoma and metastases revealed no significant
differences (D). P-values correspond to Fisher’s exact tests. To investigate if the SMARCC1 protein level was correlated with overall survival, IHC was
applied to a large custom-made TMA containing adenocarcinoma tissue cores from 1283 patients with available follow-up information. The SMARCC1 IHC
staining was evaluable in 989 of these patients. Shown in (E) are censored Kaplan–Meier survival curves as a function of the SMARCC1 IHC scores. The
individual survival curves for patients with negative and weak IHC scores were very similar and they were therefore treated as one group. The P-value
corresponds to the log-rank test comparing the survival curves. See Supplementary Table 3A for a summary of the clinical characteristics and follow-up
information available for the 989 patients. See Supplementary Table 3D for the distribution of the 989 IHC scores and their correlations with the available
clinicopathological parameters. All images are  20. Staining: brown, SMARCC1; blue, haematoxylin counterstain.
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sOverall, the IHC analysis indicated that the CBFB protein level was
increased in tumours compared with normal mucosa. This was in
agreement with the transcriptional data presented above.
SMARCC1 showed weak staining in the basal half of the
normal crypts in 9 of 10 specimens. In contrast, only 4 of 10
adenomas showed staining. Contrary to the normal mucosa,
the adenomas were uniformly stained. The frequency and
intensity of SMARCC1 staining increased borderline significantly
(P¼0.078, Fisher’s exact test) from adenoma to adenocarcinoma,
but not from adenocarcinoma to liver metastases (Figure 4D).
Generally, the staining intensities observed in the neoplastic
tissues were more intense than in the normal mucosa (Figure 4A
and B). This combined with a more uniform staining
pattern indicated that the overall SMARCC1 protein level was
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sgenerally higher in neoplastic tissue than in normal mucosa.
This is in accordance with the SMARCC1 transcriptional data
presented above.
To investigate the possible associations between the protein
levels of CBFB and SMARCC1 and the TNM stages and overall
survival, IHC was applied to a large custom-made TMA with stage
I–III adenocarcinomas for which follow-up information was
available. For both TFs, the frequency of strong staining appeared
to decrease with increasing TNM stage; however, the tendencies
were insignificant in both instances (P40.05, Fisher’s exact test;
Supplementary Tables 3C and D). When a less-stringent test for
trend (an extension of the Wilcoxon rank-sum test (Cuzick, 1985))
was applied, the tendencies were significant; P¼0.029 and
P¼0.026 for CBFB and SMARCC1, respectively (Supplementary
Tables 3C and D). Next, the possible correlations between CBFB
and SMARCC1 protein levels and overall survival were investi-
gated. Kaplan–Meier survival curves are shown in Figures 3G and
4E. Patients with tumours showing strong staining had a
significantly longer survival rate than patients with negative or
weak scoring tumours (log-rank test; CBFB P¼0.0001; SMARCC1
P¼0.0275). As both CBFB and SMARCC1 had shown weak
correlations with TNM stage, the Kaplan–Meier survival analyses
were repeated and this time was stratified by TNM stage
(Supplementary Figure 2). Bivariate Cox proportional hazard
regression analyses showed that while the CBFB protein level
remained a significant prognostic factor after stratification for
TNM stage (P¼0.002), the SMARCC1 protein level was only
borderline significant (P¼0.073) (Supplementary Figure 2). To
elaborate the analysis, it was extended from a bi- to a multivariate
analysis including all the available variables that were significant in
univariate analysis (i.e. age at surgery, sex, differentiation grade,
TNM stage, CBFB staining and SMARCC1 staining).
The multivariate analysis showed that while the CBFB protein
level remained a significant prognostic factor after stratifying for
all other available risk parameters (P¼0.011) the SMARCC1
protein level did not (Table 3).
TF expression in relation to Wnt signalling
The Wnt-signalling pathway is aberrantly activated in the majority
of CRCs and contributes directly to malignant transformation by
influencing the transcript levels of numerous genes (van de
Wetering et al, 2002; de Lau et al, 2007). To investigate if changes
in the activity of the Wnt-signalling pathway could influence the
expression level of any of the 51 TFs we utilised a colon carcinoma
model system based on LS174T cells. The model system was
engineered so that Wnt signalling mediated by b-catenin/TCF
could be abrogated on demand by induction of dnTCF1 (van de
Wetering et al, 2002), a naturally occurring inhibitor of Wnt
signalling (Waterman, 2004). Using two different microarray
platforms, the transcript levels of all 51 TFs were measured at 0
Table 3 Univariate and multivariate analysis for overall survival (Cox proportional hazard regression model)
Univariate analysis Multivariate analysis
Factor Patients (n¼959)
a HR 95% CI P-value HR 95% CI P-value
Age at surgery (years)
o65 317 1 (Reference) 1 (Reference)
465 642 1.69 1.38–2.06 o0.001 1.76 1.44–2.16 o0.001
Sex (M/F)
Male 503 1 (Reference) 1 (Reference)
Female 456 1.36 1.14–1.62 0.001 1.35 1.13–1.62 0.001
Differentiation
b
Well 13 1 (Reference) 1 (Reference)
Moderate 821 3.02 0.97–9.41 0.056 1.89 0.60–5.99 0.276
Poor 116 5.05 1.59–16.04 0.006 2.9 0.90–9.38 0.074
Tumour location
Right colon 332 1 (Reference)
Left colon 302 0.81 0.65–1.00 0.053 — — —
Rectum 325 0.85 0.69–1.05 0.131 — — —
Mucinous
b
No 883 1 (Reference)
Yes 70 1.01 0.85–1.20 0.89 — — —
UICC TNM stage
I 128 1 (Reference) 1 (Reference)
II 369 2.65 1.72–4.07 o0.001 2.33 1.51–3.60 o0.001
III 462 6.59 4.35–9.99 o0.001 5.88 3.87–8.95 o0.001
SMARCC1 staining
Negative/weak 576 1 (Reference) 1 (Reference)
Strong 383 0.82 0.68–0.98 0.029 0.95 0.78–1.14 0.57
CBFB staining
Negative/weak 491 1 (Reference) 1 (Reference)
Strong 468 0.72 0.61–0.86 o0.001 0.79 0.65–0.95 0.011
HR¼hazard ratio; TF¼transcription factor; 95% CI¼95% confidence interval.
aTo enable comparison of CBFB and SMARCC1, only patients with evaluable IHC staining for
both TFs were included. Hence of the 1283 patients from the large custom-made TMA with available follow-up information, only 959 were included in the analysis.
bPatients with
missing values were excluded from the analysis.
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sand 12h after dnTCF1 induction. Induction was validated directly
and indirectly by qRT–PCR. Directly, by demonstrating increased
levels of dnTCF1 transcript, and indirectly, by demonstrating
downregulation of c-Myc, a well-known target of the inhibited
b-catenin/TCF complex (Supplementary Figure 3). Both micro-
array platforms consistently showed deregulation of 11 TFs (seven
downregulated, including c-MYC, and four upregulated) in cells in
which Wnt signalling was inactivated (Table 2 and Supplementary
Table 8). In the majority of CRCs, Wnt signalling is abnormally
active; consequently, we would expect genes downregulated by
Wnt inactivation to be upregulated in cancer and vice versa for
genes upregulated by Wnt inactivation. For 9 of the 11 Wnt-
regulated TFs, this was exactly what we observed (Supplementary
Table 8). The seven TFs downregulated by Wnt inactivation were
all upregulated in cancer, and two of the four TFs upregulated by
Wnt inactivation (HIS1 and SSBP2) were downregulated in cancer.
The expression levels of the remaining 40 TFs did not consistently
follow Wnt-signalling activity. Hence, for B20% of the 51 TFs a
likely cause for the observed deregulation in cancer is abnormal
Wnt signalling.
DISCUSSION
This study reports the results from a thorough analysis of TF
expression changes in CRC. Our analysis of array-based transcrip-
tional profiles of 20 normal mucosa and 424 CRC samples indicated
that 51 TFs were significantly deregulated in CRC. The high number
of deregulated TFs is consistent with the dramatic transcriptional
differences observed between cancer cells and normal epithelia
(Birkenkamp-Demtroder et al, 2002; Kruhoffer et al,2 0 0 5 ) .A m o n g
the 51 candidate TFs several were already known to be deregulated
in CRC, for example c-MYC (He et al, 1998) and SOX9 (Blache et al,
2004), and also many for which this information was novel. Of the
latter, we selected four and validated their deregulation by qRT–
PCR (E2F3) and/or IHC (E2F3, SOX4, CBFB and SMARCC1). For
some of the TFs not previously reported to be deregulated in CRC,
the involvement in the tumorigenesis of other cancers has been well
established for example, SOX4 in bladder cancer and CBFB in acute
myeloid leukaemia (Kundu et al, 2002; Aaboe et al,2 0 0 6 ) .
Altogether, this indicates that many of the identified TFs are likely
to play a role in the pathogenesis of CRC.
The RB/E2F pathway has been shown to be mutationally
disrupted in many human cancers, but not in CRC (Nevins,
2001). It is still a matter of debate what role, if any, the RB/E2F
pathway plays in the development of CRC (Hildebrandt et al, 2000;
Nevins, 2001). Consistent with earlier studies not finding E2F3 in
normal lung, bladder and prostate tissue (Feber et al, 2004; Foster
et al, 2004; Cooper et al, 2006) we found that E2F3 was generally
not expressed by the normal colon epithelia. In contrast, our
analysis of CRC specimens showed high E2F3 transcript and
protein levels, and revealed a dramatic reduction in the RB1/E2F3
transcript ratio. We hypothesise that this reduction entails that the
E2F inhibitor RB1 is titrated out and that the G1/S-transition
checkpoint consequently is overridden, enabling the cancer cells to
proliferate. We found no correlation between the E2F3 expression
level and TNM stage or survival. This probably indicates that E2F3
is upregulated early in tumour development and hence not directly
related to the outcome of the disease. Our data indicate that RB/
E2F pathway inactivation may play an important role in CRC
pathogenesis even though the mechanism of inactivation is
different than in most other cancers.
To study if the 51 deregulated TFs were also involved in other
aspects of CRC pathogenesis we investigated their transcript levels
in the transcriptionally and clinically different MSS and MSI
tumour subgroups. Twelve TFs were found to be differentially
expressed between MSI and MSS tumours. However, compared
with normal mucosa, 11 of these were deregulated in both MSS and
MSI tumours making it difficult to judge if the differences between
MSS and MSI have any biological consequences. The twelfth TF
(FOXA2) was deregulated in the MSS tumours only. Hence, FOXA2
is likely to be regulating some of the many transcripts that are
differentially expressed between MSS and MSI tumours.
We next investigated if the transcript levels of any of the selected
51 TFs were capable of predicting outcome of stage II CRC. The
analyses indicated that three were putatively associated with
recurrence of MSS stage II cancer and 13 putatively with
recurrence of MSI stage II cancer. The higher number of
candidates associated with recurrence of MSI cancer may be
caused by a higher false-positive rate due to the limited number of
samples in the MSI series (9 recurrent and 56 non-recurrent)
compared with the MSS series (22 recurrent and 173 non-
recurrent). The availability of transcriptional profiles from an
independent cohort of stage II MSS cancer patients (Barrier et al,
2006) enabled us to investigate if any of the three MSS candidates
could be validated. To our knowledge, no such data set is public
available for MSI cancer; hence, the MSI candidates still await
validation. Of the three MSS candidates only SOX4 was also
associated with recurrence in the independent cohort. In both
cohorts, a high SOX4 transcript level was significantly associated
with recurrence of stage II MSS cancer and shorter recurrence-free
survival. We only observed the association in MSS cancers
consistent, with SOX4 being differentially expressed between
MSS and MSI tumours. By IHC analysis we demonstrated that
the increased SOX4 transcript levels, observed in CRC compared
with normal mucosa, also translated to the protein level. Moreover,
the IHC analysis revealed that the observed expression difference
was cancer cell specific and not related to stromal changes. In
summary, high SOX4 transcript levels identify patients with a high
risk of recurrence. These patients are likely to benefit from a more
aggressive therapy than the standard treatment offered to stage II
patients today. This study is not the first to link SOX4 expression
and clinical outcome of cancer. A recent study reported that the
SOX4 expression level correlated with survival in patients with
urinary bladder cancer (Aaboe et al, 2006).
In normal cells, the transcriptional levels of TFs are tightly
controlled by a network of signalling pathways. Several studies
have shown that deregulation of pathways, for example, the K-ras/
B-raf and Notch pathways, is a mechanism for deregulation of TFs
in cancer (Sancho et al, 2004). We speculated whether pathway
deregulation could be the mechanistic explanation for the altered
expression patterns of the selected TFs. Mutational activation of
the Wnt pathway occurs in 80–90% of all CRC cases and the
pathway is thus a likely cause for deregulation of one or more of
the TFs. Indeed, our array-based transcriptional profiling analysis
of an inducible colon carcinoma Wnt-model system corroborated
our hypothesis by indicating that 11 (B20%) of the 51 TFs were
Wnt-responsive genes. Importantly, these observations are sup-
ported by an earlier study that reported 5 of our 11 candidate Wnt-
target TFs (TGIF, SOX9, MYC, SOX4 and TEAD4) to be Wnt targets
(Van der Flier et al, 2007). Collectively, our data indicate that
deregulation of signalling pathways can lead to deregulation of
TFs; this is likely to lead to deregulation of further signalling
pathways, and in the end possibly to cellular transformation.
In the majority of CRC specimens we found the transcript and
protein levels of both CBFB and SMARCC1 increased compared
with normal mucosa. Importantly, the observed differences were
related to altered expression in the cancer cells and not the stroma
cells. Univariate survival analysis revealed that patients with high
protein levels of CBFB and SMARCC1 had a significantly longer
overall survival rate than patients with low levels. Multivariate
analysis further showed that the prognostic power of CBFB was
independent of well-established prognostic factors, including TNM
stage and differentiation grade. In keeping with the association
between low levels of CBFB protein and poor survival, we observed
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sthat cases with negative/weak CBFB protein levels were signifi-
cantly enriched in metastasis cases compared with primary
adenocarcinomas. Our transcript analyses of CBFB and SMARCC1
did not reveal any association, not even a trend, to recurrence of
stage II cancer. We cannot explain why the protein but not the
transcript level is associated with outcome. But it should be noted
that the transcript analyses were performed using stage II cancers
and time to recurrence data, whereas the protein analyses were
performed using all TNM stages and overall survival data. This
might in part explain the discrepancy. Consistent with earlier
reports, we found CBFB protein both in the cytoplasm and the
nucleus of the neoplastic cells (Tanaka et al, 1997). These locations
are in agreement with the known function of CBFB, which
constitutes half of the core-binding factor TF complex. Upon
stimulation, cytoplasmic CBFB dimerises with the one of the CBFa
factors (RUNX1–3), forming the core-binding factor complex,
which in turn translocates to the nucleus and executes its TF
function (Speck and Gilliland, 2002). Interestingly, RUNX1 is one
among the TFs that we found are upregulated. SMARCC1 is a core
member of the SWI/SNF chromatin remodelling complex, and
hence performs its function in the nucleus (Roberts and Orkin,
2004). In agreement with this, and with a previous report on the
subcellular location of SMARCC1 in prostate cancer, we found
SMARCC1 to be located in the nucleus (Heeboll et al, 2008). It is
worth noting that in recent reports, the SWI/SNF chromatin
remodelling complex, in line with our observations (SMARCC1),
has become increasingly recognised for its role in tumour
suppression (Roberts and Orkin, 2004; Nagl et al, 2007). To our
knowledge, CBFB has not previously been associated with tumour
suppressor activity. However, our data indicate that in CRC,
possibly through interaction with RUNX1 and the formation of the
core-binding factor complex, CBFB has this function. At first it
may seem peculiar that high expression levels of genes, generally
upregulated in tumours, can lead to prolonged patient survival;
there are, however, mechanisms that could explain these findings.
For example, as part of their natural defence mechanisms, normal
cells will, when exposed to carcinogens, upregulate genes that
suppress tumour development. Hence, during tumour develop-
ment there will be selection towards clones that either simply
downregulate these genes, or inactivate the signalling pathways
through which they function. In cancers produced by the latter
scenario, the tumour suppressor genes are upregulated but the
cancer cells no longer respond to the signal. Genes involved in
DNA damage response are examples of this (Bartkova et al, 2005).
In conclusion, we have identified 51 TFs that at the transcript
level are deregulated in CRC compared with normal mucosa.
Among these, E2F3 is a key component of the RB/E2F G1/S
transition checkpoint, indicating that inactivation of this check-
point may be critical for the development of CRC. We showed that
pathway deregulation, exemplified by the Wnt pathway, is a likely
mechanism causing the observed TF deregulations. Furthermore,
we found that the transcript levels of a subset of the TFs were
associated with microsatellite status. For E2F3, SOX4, CBFB and
SMARCC1, the transcript analyses were corroborated by an
in-depth IHC analysis not only confirming their increased
expression level, but also demonstrating their expression by the
cancer cells. Finally, we showed that three of the identified TFs
have prognostic potential. A high transcript level of SOX4 predicts
recurrence of stage II CRC, whereas high protein levels of
SMARCC1 and CBFB predict long-term survival of CRC.
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